Clinical Research Directory
Browse clinical research sites, groups, and studies.
Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
Sponsor: Wake Forest University Health Sciences
Summary
This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).
Official title: Elucidation of Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide (PTCy) as a Strategy for Graft Versus Host Disease Prevention in Haploidentical, Matched Related Donor and Matched Unrelated Donor Peripheral Blood Hematopoietic Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
120
Start Date
2018-07-13
Completion Date
2035-08
Last Updated
2026-01-08
Healthy Volunteers
No
Interventions
Cyclophosphamide
Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
Specimen collection
Buccal swabs will be obtained from donors for pharmacogenomics.
Locations (1)
Levine Cancer Institute
Charlotte, North Carolina, United States